<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295880</url>
  </required_header>
  <id_info>
    <org_study_id>2004LS072</org_study_id>
    <secondary_id>UMN-MT2004-26</secondary_id>
    <secondary_id>UMN-0412M65789</secondary_id>
    <nct_id>NCT00295880</nct_id>
  </id_info>
  <brief_title>Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood
      transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's
      immune system from rejecting the donor's stem cells. When the healthy stem cells from the
      donor's umbilical cord blood are injected into the patient's bone marrow they may help make
      stem cells, red blood cells, white blood cells, and platelets.

      Purpose: This phase I/II trial is studying the side effects of donor umbilical cord blood
      transplant when given directly into the bone marrow and to see how well it works in treating
      patients with hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary

        -  Determine the safety, in terms of infusional toxicity, of myeloablative unrelated donor
           double-unit umbilical cord blood (UCB) transplantation via intra-bone marrow injection
           (IBMI) in patients with advanced or high-risk hematologic malignancy.

        -  Determine whether treatment with this regimen improves the time to neutrophil
           engraftment (compared to historical controls) in these patients.

      Secondary

        -  Determine the incidence of sustained donor engraftment in patients treated with this
           regimen.

        -  Determine the relative contribution of each UCB unit to initial and sustained donor
           engraftment in these patients.

        -  Determine the incidence of grade II-IV and grade III-IV acute graft-vs-host disease
           (GVHD) and chronic GVHD in patients treated with this regimen.

        -  Determine the incidence of day 100 and 180 transplant-related mortality in patients
           treated with this regimen.

        -  Determine the probability of survival at 100 days and 1 year post-transplantation in
           these patients.

      Outline: This is a nonrandomized study.

      Patients receive a myeloablative conditioning regimen. Patients also receive
      immunosuppression, growth factor, and supportive care as in protocol MT2005-10 (NCT00309842).

      Patients receive 2 units of donor umbilical cord blood (UCB) by intra-bone marrow injection
      (IBMI) over 10 minutes each on day 0. If the IBMI procedure is not possible, then the UCB
      units are given intravenously (IV.)

      After completion of study therapy, patients are followed periodically for 5 years.

      Projected Accrual: A total of 36 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time to engraftment would not be improved compared to historical controls.
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Number of Days to Neutrophil Engraftment</measure>
    <time_frame>Daily through Day 60 post transplant</time_frame>
    <description>Number of days to neutrophil recovery observed in recipients of two umbilical cord blood units (UCB)administered i.v. Neutrophil recovery is defined as first of 3 consecutive days with ANC (absolute neutrophil count) greater than or equal to 500/ul.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving Neutrophil Recovery</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with sustained neutrophil recovery with chimerism (evidence of engraftment of both cord blood transplants) at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Evidence of Engraftment.</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who received both cord blood units and achieved sustained donor engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Acute Graft-versus-host Disease (GVHD)</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Number of patients who exhibited grade II-IV acute GVHD at 100 days post umbilical cord blood transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Transplant-related Mortality (TRM)</measure>
    <time_frame>Day 100 and Day 180</time_frame>
    <description>Number of patients who were deceased at days 100 and 180 from any cause other than relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Surviving at Day 100 and 1 Year.</measure>
    <time_frame>Day 100 and 1 year</time_frame>
    <description>Overall survival of patients-Number of patients who were alive at Day 100 and 1 year post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD)</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Number of umbilical cord blood transplant patients developing severe GVHD at 100 days post transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chronic Graft-versus-host Disease (GVHD).</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>Number of umbilical cord blood transplant patients with limited and extensive chronic GVHD.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Transplant Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving umbilical cord blood transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>The graft will be given by slow injection into each posterior iliac crest.</description>
    <arm_group_label>Transplant Patients</arm_group_label>
    <other_name>UCBT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia (AML): high risk CR1

          -  Acute lymphocytic leukemia (ALL): high risk CR1 [t(9;22), t (1:19), t(4;11) or other
             MLL rearrangements] or &gt; 1 cycle to obtain CR; CR2+. All patients must be in CR as
             defined by hematological recovery, AND &lt;5% blasts by light microscopy within the bone
             marrow with a cellularity of â‰¥15%.

          -  Chronic myelogenous leukemia (CML) excluding refractory blast crisis. To be eligible
             in first chronic phase (CP1) patient must have failed or be intolerant to imatinib
             mesylate.

          -  Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia
             with severe pancytopenia or high risk cytogenetics.

          -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone
             B-cell lymphoma or follicular lymphoma that have progressed after at least two prior
             therapies. Patients with bulky disease (nodal mass greater than 5 cm).

          -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible
             after initial therapy in CR1+ or PR1+.

          -  Large cell NHL &gt; CR2/&gt; PR2. Patients in CR2/PR2 with initial short remission (&lt;6
             months) are eligible.

          -  Lymphoblastic lymphoma.

          -  Multiple myeloma beyond PR2.

          -  Karnofsky performance status (PS) 90-100% (adults)

          -  Lansky PS 50-100% (children)

          -  Acceptable organ function

        Exclusion Criteria:

          -  Active infection at time of transplantation

          -  History of HIV infection

          -  Pregnant or breast feeding.

          -  Chemotherapy refractory large cell and high grade NHL (ie progressive disease after &gt;
             2 salvage regimens)

          -  Extensive prior therapy including &gt; 12 months alkylator therapy or &gt; 6 months
             alkylator therapy with extensive radiation.

          -  Diffuse myelofibrosis of BM (bone marrow) (any severity) regardless of primary
             diagnosis (focal fibrosis acceptable provided it involves &lt; 20% of BM volume).

          -  History of pelvic irradiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Wagner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009 Jun;43(12):935-40. doi: 10.1038/bmt.2008.417. Epub 2009 Jan 12.</citation>
    <PMID>19139736</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <results_first_submitted>March 25, 2009</results_first_submitted>
  <results_first_submitted_qc>September 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2009</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>adult diffuse large cell lymphoma</keyword>
  <keyword>adult diffuse mixed cell lymphoma</keyword>
  <keyword>adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>adult lymphoblastic lymphoma</keyword>
  <keyword>grade 3 follicular lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>childhood large cell lymphoma</keyword>
  <keyword>childhood lymphoblastic lymphoma</keyword>
  <keyword>adult acute lymphoblastic leukemia</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory cytopenia</keyword>
  <keyword>childhood acute myeloid leukemia</keyword>
  <keyword>adult immunoblastic large cell lymphoma</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients are recruited from within the Department of Blood and Marrow Transplant Program. (Patients will be co-enrolled on study MT2005-10 (NCT00309842). Eligibility for this study are identical to MT2005-10.)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Umbilical Cord Blood Transplant Patients</title>
          <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>IBMI unit could not be volume reduced</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unit randomization did not occur</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Umbilical Cord Blood Transplant Patients</title>
          <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Number of Days to Neutrophil Engraftment</title>
        <description>Number of days to neutrophil recovery observed in recipients of two umbilical cord blood units (UCB)administered i.v. Neutrophil recovery is defined as first of 3 consecutive days with ANC (absolute neutrophil count) greater than or equal to 500/ul.</description>
        <time_frame>Daily through Day 60 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days to Neutrophil Engraftment</title>
          <description>Number of days to neutrophil recovery observed in recipients of two umbilical cord blood units (UCB)administered i.v. Neutrophil recovery is defined as first of 3 consecutive days with ANC (absolute neutrophil count) greater than or equal to 500/ul.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="17" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving Neutrophil Recovery</title>
        <description>Number of patients with sustained neutrophil recovery with chimerism (evidence of engraftment of both cord blood transplants) at 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>Patients who completed treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving Neutrophil Recovery</title>
          <description>Number of patients with sustained neutrophil recovery with chimerism (evidence of engraftment of both cord blood transplants) at 6 months.</description>
          <population>Patients who completed treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Evidence of Engraftment.</title>
        <description>Number of patients who received both cord blood units and achieved sustained donor engraftment</description>
        <time_frame>1 year</time_frame>
        <population>1 patient was not evaluable due to graft failure</population>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Evidence of Engraftment.</title>
          <description>Number of patients who received both cord blood units and achieved sustained donor engraftment</description>
          <population>1 patient was not evaluable due to graft failure</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Acute Graft-versus-host Disease (GVHD)</title>
        <description>Number of patients who exhibited grade II-IV acute GVHD at 100 days post umbilical cord blood transplant.</description>
        <time_frame>100 days post transplant</time_frame>
        <population>2 patients were not graded for acute GVHD due to graft failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Acute Graft-versus-host Disease (GVHD)</title>
          <description>Number of patients who exhibited grade II-IV acute GVHD at 100 days post umbilical cord blood transplant.</description>
          <population>2 patients were not graded for acute GVHD due to graft failure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Transplant-related Mortality (TRM)</title>
        <description>Number of patients who were deceased at days 100 and 180 from any cause other than relapse.</description>
        <time_frame>Day 100 and Day 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Transplant-related Mortality (TRM)</title>
          <description>Number of patients who were deceased at days 100 and 180 from any cause other than relapse.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Surviving at Day 100 and 1 Year.</title>
        <description>Overall survival of patients-Number of patients who were alive at Day 100 and 1 year post transplant.</description>
        <time_frame>Day 100 and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Surviving at Day 100 and 1 Year.</title>
          <description>Overall survival of patients-Number of patients who were alive at Day 100 and 1 year post transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD)</title>
        <description>Number of umbilical cord blood transplant patients developing severe GVHD at 100 days post transplant.</description>
        <time_frame>100 days post transplant</time_frame>
        <population>2 patients were not yet graded for acute gvhd</population>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD)</title>
          <description>Number of umbilical cord blood transplant patients developing severe GVHD at 100 days post transplant.</description>
          <population>2 patients were not yet graded for acute gvhd</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chronic Graft-versus-host Disease (GVHD).</title>
        <description>Number of umbilical cord blood transplant patients with limited and extensive chronic GVHD.</description>
        <time_frame>1 year post transplant</time_frame>
        <population>Only 7 patients were at risk for chronic GVHD</population>
        <group_list>
          <group group_id="O1">
            <title>Umbilical Cord Blood Transplant Patients</title>
            <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chronic Graft-versus-host Disease (GVHD).</title>
          <description>Number of umbilical cord blood transplant patients with limited and extensive chronic GVHD.</description>
          <population>Only 7 patients were at risk for chronic GVHD</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Umbilical Cord Blood Transplant Patients</title>
          <description>Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>graft failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Acute GVHD Grade 3</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early based on interim statistical analysis that indicated time to engraftment will not be improved compared to historical controls. While safe, lack of faster marrow recovery supports early discontinuation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John E. Wagner, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota Blood and Marrow Transplant Program</organization>
      <phone>612-626-2961</phone>
      <email>wagne002@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

